EMA Opinion under re-examination: Daybu (trofinetide) — Acadia Pharmaceuticals B.V.

View source ↗

Summary

EMA's opinion on Daybu (trofinetide) for Rett syndrome is currently under re-examination following the initial decision.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rett Syndrome

Drugs mentioned

• Daybu (trofinetide)

Snippet

Status: Opinion under re-examination. Therapeutic area: Rett Syndrome. MAH: Acadia Pharmaceuticals B.V.. Decision date: 26/02/2026. Orphan medicine